Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL28192480 | 0.85 | GAA (0.49) | PEPDALDH1A1NPC1GAAMAPT | |
| SCHEMBL5062623 | 0.82 | PEPD (0.80) | PEPDALDH1A1NPC1GAAMAPT | |
| SCHEMBL5464327 | 0.79 | F2 (0.41) | PEPDALDH1A1NPC1GAAMAPT | |
| SCHEMBL2539930 | 0.78 | SMN1; SMN2 (0.42) | NPC1MAPTHSD17B10 | |
| Phenylurea SCHEMBL28263158 | 0.78 | GAA (0.79) | PEPDALDH1A1NPC1GAAMAPT | |
| SCHEMBL19602 | 0.76 | SMN1; SMN2 (0.60) | ALDH1A1NPC1GAAMAPTMEN1 | |
| SCHEMBL3117207 | 0.76 | ALDH1A1 (0.60) | ALDH1A1GAAMAPTKIF11KMT2A | |
| SCHEMBL1419477 | 0.76 | PRSS1 (0.38) | PEPDALDH1A1NPC1KMT2AHSD17B10 | |
| SCHEMBL1356630 | 0.76 | CA1 (0.55) | MEN1LMNAKMT2ACA1CA2 | |
| Phenylurea SCHEMBL54471 | 0.75 | GAA (0.83) | PEPDALDH1A1NPC1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 573 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | claimed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | claimed |
| EP-3740493-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | claimed |
| CN-105934431-B | Process for preparing substituted urea compounds | 比亚尔-珀特拉和CA股份公司 | 2020-11-17 | — | — | CN | claimed |
| CN-111601810-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-08-28 | — | — | CN | claimed |
| CN-109232643-A | A kind of preparation method of phosphoramide types ox feed additive | 河南湾流生物科技有限公司 | 2019-01-18 | — | — | CN | claimed |
| EP-2872511-B1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-01-16 | — | — | EP | claimed |
| EP-2872508-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2018-08-29 | — | — | EP | claimed |
| EP-2858983-B1 | TNF-ALPHA MODULATING BENZIMIDAZOLES | UCB BIOPHARMA SPRL (BE) | 2018-04-18 | — | — | EP | claimed |
| CN-107353257-A | A kind of thixotropy Low Molecular-Weight Gel and preparation method thereof | 湖北航天化学技术研究所 | 2017-11-17 | — | — | CN | claimed |
| US-4801721-A | Stereospecific synthesis of carboxyalkyl peptides | RYAN JAMES W (US) | 1989-01-31 | — | — | US | claimed |
| US-RE32761-E | ANALGESICS, ANTIRHEUMATIC AND ANTIINFLAMMATORY AGENT | STERLING DRUG INC. (US) | 1988-10-04 | — | — | US | claimed |
| US-4766110-A | INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS | RYAN JAMES W (US) | 1988-08-23 | — | — | US | claimed |
| EP-0184384-A1 | Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them | PFIZER INC. (US) | 1986-06-11 | — | — | EP | claimed |
| US-4581354-A | ANALGESICS;ANTI-RHEUMATIC AND ANTI-INFLAMMATORY AGENTS | STERLING DRUG INC. (US) | 1986-04-08 | — | — | US | claimed |
| EP-0073143-B1 | NOVEL COMPLEX AMIDO AND IMIDO DERIVATIVES OF CARBOXYALKYL PEPTIDES AND THIOETHERS AND ETHERS OF PEPTIDES | Ryan, James Walter (US) | 1985-11-21 | — | — | EP | claimed |
| EP-0060640-B1 | 5,6,7-TRINOR-4,8-INTER-M-PHENYLENE PGI DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TORAY INDUSTRIES, INC. (JP) | 1985-11-13 | — | — | EP | claimed |
| EP-0073143-A2 | Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides | Ryan, James Walter (US) | 1983-03-02 | — | — | EP | claimed |
| EP-0048159-A2 | Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents | UNIVERSITY OF MIAMI (US) | 1982-03-24 | — | — | EP | claimed |
| US-4032652-A | SUBSTITUTED 2H-PYRAN-2,6(3H)-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH DERIVATIVES AND METHODS OF INHIBITING THE ANTIGEN-ANTIBODY REACTION | SMITHKLINE CORPORATION (US) | 1977-06-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, TDO2, IDO1 | PEPD 244/4885ALDH1A1 631/4885NPC1 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.